Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) shares gapped up before the market opened on Monday. The stock had previously closed at $16.51, but opened at $17.10. Astellas Pharma shares last traded at $16.96, with a volume of 51,594 shares changing hands.
Analysts Set New Price Targets
Separately, Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.
Check Out Our Latest Research Report on ALPMY
Astellas Pharma Price Performance
The stock has a market cap of $30.58 billion, a PE ratio of 9.85 and a beta of 0.06. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.93 and a current ratio of 1.20. The business has a 50 day moving average price of $15.33 and a two-hundred day moving average price of $14.85.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.06). Astellas Pharma had a return on equity of 26.13% and a net margin of 16.18%. The business had revenue of $3.98 billion for the quarter, compared to the consensus estimate of $3.79 billion. Research analysts expect that Astellas Pharma Inc. will post 1.40 earnings per share for the current fiscal year.
About Astellas Pharma
Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, and is headquartered in Tokyo. Astellas develops treatments across areas including oncology, urology, immunology and women’s health. Its medicines include Xtandi (enzalutamide), used to treat certain forms of prostate cancer, and Prograf (tacrolimus), an immunosuppressant used in organ transplantation.
Further Reading
- Five stocks we like better than Astellas Pharma
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
